NINJ1 and Acute hepatitis: A recently reported NINJ1-neutralizing monoclonal antibody that hindered the formation of NINJ1 polymers and effectively reduced liver injury in mouse models of acute hepatitis highlights the potential therapeutic value of neutralizing NINJ1 activity [71].